Interventional Cardiology Devices Market

The global interventional cardiology devices market is projected to grow from USD 31.12 billion in 2026 to USD 42.39 billion by 2031, at a CAGR of 6.4% over the forecast period. Growth is driven by the rising worldwide prevalence of cardiovascular disease, particularly coronary artery disease and structural heart disorders, linked to population aging, sedentary lifestyles, and increasing rates of diabetes and obesity. A growing preference for minimally invasive, catheter-based procedures over conventional open-heart surgery is further accelerating adoption, owing to shorter hospital stays, faster recovery, and lower procedural risk. Next-generation drug-eluting stents, transcatheter heart valves, intravascular imaging, physiology-guided systems, and bioresorbable technologies continue to raise procedural accuracy and broaden the range of treatable conditions.

At the same time, intravascular imaging and physiology-guided assessment—IVUS, OCT, and pressure-based diagnostics such as fractional flow reserve (FFR)—are improving procedural precision and expanding access to complex PCI and structural heart interventions in more centers worldwide. The strong shift toward transradial access, supported by patient benefits, faster recovery, and lower overall costs, is driving innovation in catheters, guidewires, stents, and vascular closure devices with smaller profiles. These capabilities improve diagnostic accuracy and procedural decision-making, reduce unnecessary interventions and repeat procedures, and align closely with value-based care.

To know about the assumptions considered for the study download the pdf brochure

In addition, the migration of selected procedures to outpatient and ambulatory care settings in developed markets, combined with the expansion of catheterization lab capacity in emerging economies, is fueling demand for efficient, cost-effective interventional devices. The transformation of cath labs into digital environments, through AI-enabled imaging, workflow automation, and data-driven clinical decision support, is emerging as a major growth driver. Meanwhile, value-based care models, pricing pressures, and evolving regulatory and clinical evidence requirements are intensifying competition, prompting manufacturers to innovate, differentiate their portfolios, and pursue global partnerships and acquisitions at a faster pace.

Major players in the interventional cardiology devices market include Boston Scientific Corporation (US), Medtronic (US), Abbott (US), Edwards Lifesciences Corporation (US), and Terumo Corporation (Japan). These companies offer comprehensive portfolios spanning coronary, peripheral, and structural heart interventions, including drug-eluting stents, angioplasty and drug-coated balloons, guidewires, atherectomy and intravascular lithotripsy systems, intravascular imaging, physiology-guided diagnostics, and structural heart solutions. Continued investment in next-generation device platforms, clinical evidence, and emerging-market expansion supports modernization of cath-lab workflows and improvement of long-term clinical outcomes.

In April 2026, Medtronic completed the acquisition of CathWorks Ltd., a developer of angiography- based physiology technology for coronary artery disease. The acquisition strengthens Medtronic's coronary and interventional cardiology portfolio by enhancing its capabilities in physiological assessment and treatment planning for cardiovascular disease.
In April 2026, Abbott received US FDA clearance and CE Mark approval for its next-generation Ultreon 3.0 coronary imaging platform. The AI-powered intravascular ultrasound (IVUS) platform integrates advanced imaging and software capabilities to support the assessment and treatment of coronary artery disease during interventional procedures.

Boston Scientific Corporation

Boston Scientific Corporation (US) is a leading global medical device company with a deep, well-integrated interventional cardiology portfolio spanning coronary, peripheral, and structural heart procedures. Its offering includes drug-eluting stents, angioplasty balloons, guidewires, atherectomy and intravascular lithotripsy systems, and a growing structural heart franchise covering interventions such as left atrial appendage closure and high-risk PCI. The company maintains a strong position in US cath labs supported by extensive clinical evidence, physician confidence, and compatibility with existing infrastructure. Boston Scientific continues to invest in device innovation, clinical trials, strategic acquisitions, and domestic manufacturing expansion to broaden indications and meet rising procedure volumes across hospitals and ambulatory surgery centers.

Abbott

Abbott (US) is a global healthcare company with a comprehensive interventional cardiology portfolio that combines coronary stents, intravascular imaging, and physiologic assessment tools used to guide PCI worldwide. Its integrated platforms enable physicians to assess lesion severity, optimize stent placement, and evaluate procedural results in real time, supporting both standard and complex coronary interventions. The integration of imaging (IVUS and OCT) and physiology improves diagnostic accuracy and procedural decision-making, helping reduce unnecessary interventions and repeat procedures. Abbott continues to advance AI-enabled imaging—as reflected in its Ultreon optical coherence tomography software—and a broad coronary and structural heart range, aligning its offering with value-based care priorities across hospital and outpatient settings.

Market Ranking

In 2025, the interventional cardiology devices market remained consolidated, with Boston Scientific Corporation (US), Medtronic (US), Abbott (US), Edwards Lifesciences Corporation (US), and Terumo Corporation (Japan) collectively accounting for approximately 64–68% of the market. As healthcare systems intensified their focus on minimally invasive care, procedural precision, and value-based outcomes, vendors accelerated innovation across next-generation stents, intravascular imaging, physiology-guided diagnostics, structural heart devices, and calcium-modification technologies.

1. Boston Scientific led the market through a broad coronary, peripheral, and structural heart portfolio, spanning drug-eluting stents, balloons, atherectomy, and intravascular lithotripsy (strengthened by its acquisition of Bolt Medical), backed by deep cath-lab penetration and strong clinical evidence.
2. Medtronic leveraged a broad cardiovascular portfolio, advanced stents and drug-coated balloons, and catheter-based delivery systems, supported by long-standing physician and hospital relationships across high-volume and outpatient settings.
3. Abbott advanced its position through coronary and structural heart devices, intravascular imaging (IVUS/OCT), and physiology-guided diagnostics, including AI-enabled OCT imaging via its Ultreon platform.
4. Edwards Lifesciences maintained a strong position in structural heart, particularly transcatheter heart valve therapies, supported by extensive clinical evidence and continued innovation in minimally invasive valve repair and replacement.
5. Terumo sustained strong traction with a comprehensive coronary and access portfolio, including guidewires, catheters, and transradial access solutions, supporting the global shift toward smaller-profile, radial-access interventions.

Across the competitive landscape, vendors have increasingly focused on minimally invasive access, intravascular imaging, physiology-guided decision-making, and calcium modification and structural heart technologies to differentiate themselves on procedural precision, safety, and long-term outcomes. These developments reflect the growing maturity of the interventional cardiology devices market, as providers continue to invest in advanced, evidence-backed device platforms to support complex coronary and structural heart care.

Related Reports:

Interventional Cardiology Devices Market by Type (Angioplasty Stent, Catheter, Guidewire, Atherectomy, Drug Eluting/Cutting Balloon, IVUS/OCT, Vascular Closure Device, Plaque Modification Device, Hemodynamic Alteration Devices) - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]